摘要
Currentlytheclinicalmanagementofbreastcancerreliesonrelativelyfewprognostic/predictiveclinicalmarkers(estrogenreceptor,progesteronereceptor,HER2),basedonprimarytumorbiology.Circulatingbiomarkers,suchascirculatingtumorDNA(ctDNA)orcirculatingtumorcells(CTCs)mayenhanceourtreatmentoptionsbyfocusingontheverycellsthatarethedirectprecursorsofdistantmetastaticdisease,andprobablyinherentlydifferentthantheprimarytumor'sbiology.Toshiftthecurrentclinicalparadigm,assessingtumorbiologyinrealtimebymolecularlyprofilingCTCsorctDNAmayservetodiscovertherapeutictargets,detectminimalresidualdiseaseandpredictresponsetotreatment.Thisreviewservestoelucidatethedetection,characterization,andclinicalapplicationofCTCsandctDNAwiththegoalofprecisiontreatmentofbreastcancer.
出版日期
2016年01月11日(中国期刊网平台首次上网日期,不代表论文的发表时间)